|
Patent landscape, scope, and claims: |
United States Patent 5,844,002 Scope and Claims Analysis: Optically Pure R(−) Albuterol Method-of-Use Coverage and US Patent Landscape
United States Patent US 5,844,002 is directed to method claims for inducing bronchodilation or relieving bronchospasm by administering optically pure R(−) albuterol, with dependent claim fallbacks that tighten isomer purity, route of administration (inhalation vs oral), and dose ranges (inhaled and oral). The patent’s practical enforcement leverage is strongest against manufacturers and filers whose clinical submissions and labeling practices in the US require prescribing or administering a product that falls inside the claim’s isomeric composition thresholds and dose/route limitations.
What does US 5,844,002 claim: optically pure R(−) albuterol bronchodilation methods?
Core claim concept (independent claim 1).
Claim 1 requires all of the following:
- A method of inducing bronchodilation or providing relief of bronchospasm.
- Administering to an individual a quantity of optically pure R(−) albuterol sufficient to induce bronchodilation.
Scope implication.
“Optically pure” functions as the central limiting feature. Even without explicit percent language in claim 1, the dependent claims operationalize “optically pure” into enforceable compositional thresholds (at least 90% and at least 99% R(−)).
How do dependent claims narrow US 5,844,002 beyond optically pure albuterol?
Isomer purity fallbacks (claims 2 and 3)
- Claim 2: R(−) albuterol is ≥90% by weight, with S(+) ≤10% by weight.
- Claim 3: R(−) albuterol is ≥99% by weight, with S(+) ≤1% by weight.
Scope implication.
- Any R-enantiomer product with S(+) content >10% falls outside claims 2 and 3.
- A product with R(−) ≥90% but <99% maps to claim 2 but not claim 3 (depending on how “optically pure” is construed in claim 1).
- A product with R(−) ≥99% potentially lands inside claim 1, claim 2, and claim 3.
Route of administration (claims 4–6)
- Claim 4: optically pure R(−) albuterol is administered by inhalation.
- Claim 6: optically pure R(−) albuterol is administered orally.
Scope implication.
A label or method protocol restricted to inhalation does not automatically infringe oral limitations, and vice versa. This matters for US generics and 505(b)(2) route variants.
Dose ranges by route (claims 5 and 7)
- Claim 5 (inhalation): about 30 μg to 90 μg.
- Claim 7 (oral): about 1 mg to 8 mg.
Scope implication.
- If a branded or generic product’s labeled dose units and dosing regimens consistently fall outside these ranges, infringement risk drops materially.
- If dosing can be adjusted into the claimed windows by physicians, enforceability may depend on whether the asserted method is practiced under an inducing or instructive labeling/marketing framework.
Oral formulation limitation to syrup (claims 8–9)
- Claim 8: oral optically pure R(−) albuterol administered as a syrup.
- Claim 9: oral dose range (claim 7) administered as a syrup.
Scope implication.
- These claims are narrower than claim 6 alone. A tablet, solution, suspension in a different presentation, or unit-dose form may avoid claims 8 and 9 unless it is still considered a “syrup” in claim construction.
- If a product is marketed as syrup specifically, claims 8 and 9 become a direct licensing and litigation focal point.
Adverse-effects reduction theory (claim 10)
- Claim 10: inducing bronchodilation while simultaneously reducing concomitant liability of adverse effects associated with racemic albuterol.
Scope implication.
- Claim 10 is a method-of-use claim that adds a functional outcome: reduced adverse effects liability relative to racemic albuterol.
- The functional limitation can increase evidentiary complexity in enforcement because it ties infringement to a reduction outcome, not only to dose and composition. In practice, it pushes leverage toward products with clinical differentiation versus racemic albuterol.
How broad is US 5,844,002 versus typical albuterol enantiomer patents?
US 5,844,002 is not a manufacturing-process patent. It is a clinical method-of-use patent anchored on administration of optically pure R(−) albuterol.
Breadth drivers
- Method-of-use format: captures “use” practices rather than only particular synthesis steps.
- Route + dose + purity layering: permits multiple independent “entry points” (e.g., claim 1 plus later compositional and dose restrictions).
- Oral vs inhalation segmentation: narrows to particular prescribing routes.
Breadth constraints
- Purity thresholds: claim scope is bounded by R(−) content and S(+) content (claims 2 and 3).
- Dose windows: specific μg and mg ranges in claims 5 and 7 constrain infringement.
- Syrup constraint: claims 8 and 9 restrict oral presentations to syrup.
- Adverse-effects outcome: claim 10 requires reduction of adverse-effect liability associated with racemic albuterol.
When does US 5,844,002 lose exclusivity: expiration timeline for US 5,844,002
No expiration or terminal disclaimer data is included in the prompt, and exclusivity timing depends on the patent’s filing date, prosecution history, and whether any PTA/terminal disclaimer applied. With the provided information limited to claims, a complete accuracy-grade exclusivity timeline cannot be produced.
What patents surround US 5,844,002 in the R(−) albuterol landscape?
A full US patent landscape requires at least one of: the patent’s bibliographic data (title, filing date, assignee, inventor), the full patent family, or the Orange Book/claim-to-approval mapping for R(−) albuterol products. The prompt provides claim text only, and there is no dataset of related US patents, continuations, reissues, or family members to enumerate with specificity.
What generic entry risks exist for R(−) albuterol methods covered by US 5,844,002?
With claim scope limited to optically pure R(−) albuterol methods (specific purity thresholds, route, dose, syrup presentation) the generic entry risk depends on whether a generic filer’s proposed product:
- contains R(−) albuterol at the purity levels that map to claims 2 and/or 3;
- uses a route (inhalation vs oral) that matches asserted claim(s);
- fits dose ranges in claims 5 and 7;
- is marketed as syrup if claims 8 and 9 are asserted; and
- supports a labeling narrative or prescribing instruction that fits claim 10’s “reduced adverse effects” limitation.
A filer that can position its product outside purity thresholds, dose windows, or syrup presentation materially reduces infringement exposure for those dependent claims. A product that conforms closely to R(−) purity and dose will carry higher litigation risk even if it changes formulation details, unless it can exit the specific route/dose/presentation constraints.
How does US 5,844,002 compare with racemic albuterol intellectual property?
Key contrast embedded in the claims.
- Racemic albuterol uses both enantiomers (R(−) and S(+) ) without the same “optically pure R(−)” limitation.
- The patent’s claim 10 adds a functional distinction: reducing adverse effects liability “associated with racemic albuterol.”
Scope consequence.
- Competitors marketing racemic albuterol as such do not meet the optically pure R(−) requirement, unless they market and administer an R(−) enriched product.
- The IP value of US 5,844,002 sits in the enantiomer purity, dosing, and administration method, not in a generic “albuterol bronchodilation” concept.
What is the litigation and regulatory status of US 5,844,002 (Orange Book, Paragraph IV, settlements)?
No litigation docket, Orange Book listing, NDA/BLA numbers, FDA approval pathway details, or settlement records are provided in the prompt. Without these inputs, a complete US regulatory and litigation status summary cannot be produced with factual precision.
Claim chart style breakdown: US 5,844,002 scope mapped to product attributes
| Assertable feature in US 5,844,002 |
Claim(s) |
Product attribute that must match to infringe |
| Method to induce bronchodilation or relieve bronchospasm via R(−) albuterol |
1 |
A clinician/patient administration practice that induces bronchodilation using optically pure R(−) albuterol |
| R(−) purity ≥90% by weight, S(+) ≤10% by weight |
2 |
Enantiomer composition meets threshold |
| R(−) purity ≥99% by weight, S(+) ≤1% by weight |
3 |
Very high enantiomeric purity |
| Inhalation route |
4 |
Product is administered by inhalation |
| Inhaled dose about 30 μg to 90 μg |
5 |
Delivered dose range falls within window |
| Oral route |
6 |
Product administered orally |
| Oral dose about 1 mg to 8 mg |
7 |
Labeled/practiced dose range falls within window |
| Oral syrup presentation |
8, 9 |
Formulation is marketed/used as syrup |
| Reduced adverse effects liability versus racemic albuterol |
10 |
Functional outcome tied to adverse effects profile relative to racemic comparator |
Which products or companies would be most exposed under US 5,844,002?
Exposure ranks highest for any US market participant whose product:
- is R(−)-dominant with S(+) controlled to ≤10% (claim 2) or ≤1% (claim 3),
- uses a route and dosing regimen matching claims 4–7,
- and, for the narrowest dependence, is marketed as syrup (claims 8 and 9),
- with the additional differentiation narrative relevant to claim 10 (reduced adverse effects vs racemic).
Key takeaways
- US 5,844,002 is a method-of-use patent centered on administering optically pure R(−) albuterol to induce bronchodilation or relieve bronchospasm.
- The claim scope is structured by enforceable limits: enantiomer purity thresholds (≥90% and ≥99% R(−)), route (inhalation vs oral), dose ranges (30–90 μg inhaled; 1–8 mg oral), and oral syrup presentation.
- Claim 10 adds a functional outcome of reduced adverse-effects liability vs racemic albuterol, increasing proof and litigation complexity but also tightening the differentiation theory.
- A full exclusivity and landscape assessment requires bibliographic and regulatory mapping that is not included in the prompt; the scope analysis above is fully grounded in the provided claim language.
FAQs
-
Does US 5,844,002 cover R(−) albuterol products with less than 90% R(−) purity?
No, claims 2 and 3 require ≥90% or ≥99% R(−) by weight; claim 1 still requires “optically pure” R(−), and less-pure products would fall outside the disclosed optically-pure framework.
-
Can an inhalation-only product avoid US 5,844,002 oral syrup claims?
Yes, claims 8 and 9 require oral administration as a syrup; an inhalation-only product does not meet those dependent limitations.
-
What happens if a generic label’s inhaled dose is outside 30–90 μg?
It reduces risk for claim 5, though other independent features (purity and method) could still be asserted under broader claims depending on dosing practices.
-
Is claim 10 broader than the composition and dose limitations?
Claim 10 is broader in concept (it uses a “simultaneously reducing adverse effects” functional outcome) but still depends on administering optically pure R(−) albuterol sufficient for bronchodilation.
-
Do manufacturing changes (e.g., different synthesis) eliminate infringement of a method-of-use patent?
Not by themselves; because US 5,844,002 is framed around administration and use outcomes/attributes, product composition, route, dose, and presentation remain central.
References
- United States Patent 5,844,002 (claims provided in prompt).
More… ↓
⤷ Start Trial
|
